Wishing and praying to stabilize the situation up there. Great people.
Seems like they planned on, and are anticipating that they have to be the price leader by a far stretch to overcome 3d to market, questionable safety profile, and possible success of Belphen data. This could be a game changer in the entire space. I do hope that if people first try Contrave and have bad results, or use, that they do not throw in the towel for Belviq as well. Of course if they have good results, we do lose a lot of sales at that pricing, and there is no question our pricing would need to be revisited.
The price hardly changed the entire day. Strange beast . . . I'll gladly take a green day to buffer the FUD all night and day tomorrow.
On queue - start the "FUD News" and critique now!
I think if Lorcaserin does not win the Prix Galien award for which it has been nominated this year, it would have a chance again for nomination next year since Belphen and smoking cessation results, and who knows what other, will be much more well known by that next 2015 date.
I do not think they need a PR for this. This position either performs or not. Strategically it must add value or they wasted their time with the hire. I am sure they are confident it will. The position has been open for some time. In my own opinion, a PR on the hire would be cheap, insignificant news.
Also, it only highlights what many wanted (longs that is) somebody with more experience in that role. The cons of a PR would only emphasize the naysayer #$%$ that Arena is not well connected with WS. Whether they are or not, the guy needs to be fact based and not destroy or cloud the fundamental science-based approach and branding the company has chosen. Let the other companies be flashy and stretch machines of the truth.
Arena is not going to get into being flashy if that is what people want with more aggressive, weekly communications. I'm hoping this pro works or participates a bit closer with Eisai's management and marketing team.
One can sit here and attack Contrave, but it should open more eyes to medicines for obesity management. I find that the discussions now will be more developed between physician and patient.
If the physician is well read on the topic, she/he would discuss the drugs that are available and the pros and cons of each. One will have a black box warning, similar efficacy (unless there is a b.s. session from the sales rep and doctor cannot look into the true results), no time on the market yet, but possibly cheaper than the safest one going, Belviq. The doc could also explain Contrave is comprised of two existing generics, but Belviq is a new compound.
The very good news is that Belviq has a safe record on the market now for over one year getting great results from users. More good news is that Belviq has not been pumped like a fad diet drug, at all. It is a legitimate, science based compound that is being recognized by the medical community.
If a doc prescribes Contrave over Belviq, that might also help in making contrasts and discussion among users, and amongst the physicians. We need competition and discussion in this area, not less of it. We need more ad dollars in the arena, not less of it. If Belviq is the best of the three, it will clearly shine.
Great background. Interest and participation in his community, at least on paper, shows good character. I like someone who sees some hands-on work like Big Brothers / Big Sisters as worthwhile outside of work.
Hoping he has some good energy and solid ideas in his new position for Arena. Good luck Mr. Rieger!
I realize there are pumper-galore types also, but my goodness these everything is bad, basher types are like a 100,000 clones, just so robot like and relentless. Imagine a re-channeling of this same weekly work productivity and commitment.
Yes, and there are probably more. Thanks as LSD is in the same category or level as the rest.
Lorcaserin Application - for other national public interest and concern - pervasive drug addictions?
I'd love to know what the primary brain mechanisms of addiction to heroin, to meth, to cocaine, to tobacco have in common. Maybe nothing? In other words, although the BMI body types of heroin and meth addicts do not usually fit the criteria for prescription under the current label, I do wonder if Lorcaserin would work on these addictions also. Maybe not. Worth knowing perhaps. I guess the other thing that would have to be considered if someone tries it with a qualified bmi candidate would be the possible interaction with the heroin, meth, or cocaine already in the body system.
If anyone smart has read anything on it and wants to provide comment, here or on IV, I'd be quick to read your post.
The lack of strategic PR teams or lack of b awls by Arena's management team continues. Data of what scripts did last year indicated this week or time period was going to be a flat WoW. So fill in the gaps with information like smoking cessation data? Of course not. Release something to talk about? Of course not.
Take a swing at the ball Arena. It's not going to get the entity into trouble if you pre-release tie-bit of information that is available and backed-up later. The down news weeks could be filled in with so much if this company would get off its butt and think about communication.
Since Chantix just got a thumbs down, the Obesity Week (as a side bar of course as it is about obesity and weight management) is a great time to release data on the smoking cessation. Even if the release is off the topic, outside the confines of the conference now is the time to release information, albeit maybe it is not organized in a formal report quite yet. If they know what the details of the data are and they are similar to Chantix results with more safety, why not release it now while the iron is hot?
Because the mind drifts on current events, quickly, if a PR team can create / correlate, put two events together for meaning, close in time, the emphasis and attention span to the information might be much greater. Therefore, I guess what I'm saying (trying to), is that Chantix just got the bad news on the retention of the warning label (at best you could say this is neutral news) and then here comes along another FDA approved medicine for another health issue, with a safer profile, at or about the same time to fill the void. Granted it is not yet on the label, but users are reporting smoking cessation effects. The trial was done and completed by now.
Since Chantix is on the minds of those following smoking cessation, RIGHT NOW would appear to be a great time to release Lorcaserin smoking cessation data if it is available and somewhat organized.
So true - it' been said a million times, crime does not pay. But in this instance, this went on for a very long time (and is going on with other firms), and I am sure a $1mm fine means zero in terms of the profitability from the deed. It's part of the business model.
The analysis in part is likely "attorneys will cost this much, the potential civil penalty with good attorneys will cost this much, employee time and speak devoted to the allegations and charges will cost this much, and our net from all of that, given these expenses, is $. Worth it to continue in some manner. This cannot reasonably be jail time with good attorneys. Our practice will be to instill procedures that always keep these possible deeds in many separate parts, couched as only being a total "entity" act that in total was/is an oversight of the whole puzzle and its ramifications when put together. In essence if we do not put one person in charge of the entire process, but rather simply combine parts to achieve this, no one really is in charge of or knows who is doing what, at what time, or in totality, We should be able to use attorneys to reduce these acts to fines and avoid having people going to jail."
of closing prices toward end of the day. Flooded the end of the day transactions to ensure it received favorable price action in harmony with its strategies in equities.
Then you look at Arena's trading (go to a place like NASDAQ and study the trading lots - mostly 100s and 200s sometimes 300s at a time). There are many exceptions for sure but there is a majority of 100s and 200s going in and out all day.
If this does not look like HFT, flooding trades back and forth to trap the pricing in favor of strategic sentiments of an equity, what is? I guess what seems somewhat obvious, if you put in an order for let's say 2,500 shares and it gets chunked out in 100s and 200s to fill, at pricing that is slightly less or more than your direction, because of HFT in and out before your transaction hits, you may as well be a guy with three kids who waits in line at Disney for a ride, and then has one of the Kardashians steps in line in front of you just as they arrive on a helicopter. Sorry, we're first. We heard this ride is really good so we do not want to wait any longer. Oh, after we're done, you can go.